Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years.

ABSTRACT:

Background

The emergence of immune-escape variants of severe acute respiratory syndrome coronavirus 2 warrants the use of sequence-adapted vaccines to provide protection against coronavirus disease 2019.

Methods

In an ongoing phase 3 trial, adults older than 55 years who had previously received three 30-μg doses of the BNT162b2 vaccine were randomly assigned to receive 30 μg or 60 μg of BNT162b2, 30 μg or 60 μg of monovalent B.1.1.529 (omicron) BA.1-adapted BNT162b2 (monovalent BA.1), or 30 μg (15 μg of BNT162b2 + 15 μg of monovalent BA.1) or 60 μg (30 μg of BNT162b2 + 30 μg of monovalent BA.1) of BA.1-adapted BNT162b2 (bivalent BA.1). Primary objectives were to determine superiority (with respect to 50% neutralizing titer [NT₅₀] against BA.1) and noninferiority (

SUBMITTER: Winokur P 

PROVIDER: S-EPMC9933930 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature